Rasagiline for Restless Legs Syndrome
This study will determine whether an investigational medication (Rasagiline) has an effect on Restless Legs Syndrome (RLS). The study is open to adults 18 and older who have RLS.
Participation involves completing a physical exam, completing questionnaires, and taking study drug for 12 weeks. The time commitment includes 4 study visits over a 12 week period, each lasting about 1-2 hours. You will receive a phone call 2 weeks after completing study drug, for a total of 14 weeks participation.
If you would like more information on this study please contact:
Nancy Foldvary-Schaefer, DO, Director, Cleveland Clinic Sleep Center at 216.445.2990 or
Judy Meinert, Research Coordinator, at 216.445.7168.
Searching for "Sleep Friendly" Therapies for a sleep population: A Double-Blind, Placebo-Controlled randomized trial to assess the effects of Lacosamide on sleep and wake in adults with Focal Epilepsy
Sleepiness and fatigue are the most common complaints of people with epilepsy and can have a negative impact on quality of life. Though unproven, these problems are often blamed on anti-seizure medications. Cleveland Clinic investigators are studying the impact of the newest anti-seizure medication Lacosamide (Vimpat®) on sleep and wakefulness in adults with focal (partial onset) seizures.
Focal epilepsy, also called partial epilepsy, is a disorder in which seizures are preceded by an isolated disturbance such as a twitching of a part of the body, a particular sensation or feeling, or some other disturbance in consciousness. The study is open to adults 18 and older with focal seizures.
Participation involves a physical exam, sleep testing at the Sleep Center, blood tests, completion of study questionnaires/diaries, and a random assignment to either take the study drug or placebo (often called a “look alike” or “sugar pill”) for 5 to 8 weeks. There are 5 study visits and participants will receive compensation for time spent in the study.
If you would like more information on this study please contact:
Nancy Foldvary-Schaefer, DO, Cleveland Clinic Sleep Disorders Center at 216.445.2990 or
Judy Meinert, Study Coordinator at 216.445.7168
